Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Arman Borhan

Pain Medicine Mishawaka, IN Medical Doctor

NPI 1689705535 CMS profile 303851

3212 Hickory Rd, Suite B, Mishawaka, IN 46545

Open in the dashboard

General payments

$2,439

61 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Arman Borhan of Mishawaka, IN is reported in the CMS Open Payments database as having received $2,439 across 61 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 57th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $41 2
2023 General $157 9
2022 General $102 6
2021 General $124 7
2020 General $237 12
2019 General $1,778 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Arman Borhan
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Arman Borhan were reported at $0. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.

Show as a table
Year Arman Borhan Pain Medicine median Middle half National median
2019 $1,778 $409 $115–$1,311 $163
2020 $237 $214 $66–$666 $114
2021 $124 $299 $84–$899 $132
2022 $102 $335 $103–$1,149 $149
2023 $157 $376 $114–$1,228 $160
2024 $41 $387 $115–$1,173 $164
2025 $0 $402 $130–$1,173 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Medtronic Vascular, Inc. $1,554 9 payments
  2. AbbVie, Inc. $124 7 payments
  3. Medtronic USA, Inc. $118 4 payments
  4. Medtronic, Inc. $80 4 payments
  5. Boston Scientific Corporation $61 4 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $55 4 payments
  7. Pfizer Inc. $44 3 payments
  8. Lilly USA, LLC $38 3 payments
  9. Novartis Pharmaceuticals Corporation $35 3 payments
  10. Biodelivery Sciences International, Inc. $30 2 payments
  11. Other $302 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $1,335 59 payments
  2. Travel and Lodging $1,104 2 payments
Products named General payments · program years 2019–2024
  1. ClosureFast $1,554 9 payments
  2. ADAPTIVESTIM $92 3 payments
  3. UBRELVY $79 4 payments
  4. INTELLIS ADAPTIVESTIM $57 3 payments
  5. AIMOVIG $56 4 payments
  6. RELISTOR $55 4 payments
  7. QULIPTA $45 3 payments
  8. EMGALITY $38 3 payments
  9. BELBUCA $30 2 payments
  10. REYVOW $26 2 payments
  11. Other $451 28 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

604

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$9,570

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

41.6%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 188 $3,393
Tramadol Hcl Er Tramadol Hcl Brand 29 $1,937
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 34 $916
Tramadol Hcl Generic 71 $804
Gabapentin Generic 81 $780
Tizanidine Hcl Generic 37 $507
Pregabalin Generic 56 $447
Cyclobenzaprine Hcl Generic 49 $389
Amitriptyline Hcl Generic 15 $238
Methylprednisolone Generic 17 $103

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$101,311

Medicare's payments for the services billed

Medicare patients

361

Average age 75

Services billed

1,782

237 women, 124 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 44%
Diabetes 34%
Chronic kidney disease 34%
Ischemic heart disease 30%
COPD 27%
Heart failure 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

61 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record